RxDoctor Payments Data

Norberto Vargas, MD

Pain Medicine · Paris, TXNPI 1861410995

Payments from drug & device makers

$670in general payments, 2019–2025

Across 21 payments — averaging $31.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertos Medical, Inc.$123
  • Ipsen Biopharmaceuticals, Inc$121
  • Boston Scientific$98
  • Neurocrine Biosciences, Inc.$85
  • Indivior Inc.$75
  • Braeburn Inc.$44
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$65698%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$670 in reported general payments places this provider in the 20th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,031
Medicare patients
331
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,217$102,444
OxycontinOxycodone Hcl84$33,961
Fentanyl301$26,211
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen473$19,475
Xtampza ErOxycodone Myristate33$12,070
Oxycodone Hcl244$6,699
Morphine Sulfate ErMorphine Sulfate138$4,017
Hydromorphone Hcl101$2,385
Pregabalin100$1,948
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$1,296
Acetaminophen-CodeineAcetaminophen With Codeine37$862
Methadone Hcl33$526
Tramadol Hcl46$463
Morphine Sulfate15$284
Gabapentin23$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate$14$1,58026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Paris

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →